Oviva is a company.
Oviva has raised $113.0M across 3 funding rounds.
Key people at Oviva.
Oviva has raised $113.0M in total across 3 funding rounds.
Oviva is a leading European digital health company that provides virtual clinics specializing in weight-related conditions such as obesity, type 2 diabetes, prediabetes, and hypertension. It combines personalized coaching by certified dietitians with an intuitive mobile app to empower patients to make sustainable lifestyle changes, improve health outcomes, and reduce the burden on healthcare systems. Oviva serves patients primarily through partnerships with statutory health insurers and national healthcare systems in countries including the UK, Germany, Switzerland, and France, having supported over 800,000 patients across Europe by 2024[1][4][7].
The company’s product integrates digital therapeutics with human coaching, enabling patients to track meals, physical activity, and weight, while maintaining regular communication with dietitians via chat. This approach addresses chronic diet-related health problems by improving patient motivation and adherence to healthier behaviors, ultimately aiming to reduce healthcare costs and improve quality of life[1][5][7].
Oviva was founded in 2014 in Switzerland by Kai Eberhardt (CEO), Manuel Baumann (CTO), and Mark Jenkins (UK Managing Partner & Medical Director). The idea emerged from the need to provide scalable, effective dietary and lifestyle interventions for chronic conditions that are traditionally underserved by face-to-face healthcare due to resource constraints. Early traction was achieved through collaborations with medical doctors and clinics, leading to contracts with health insurers and national health systems, including the UK’s NHS Diabetes Prevention Programme launched in 2019. The company has since expanded its reach and services across multiple European countries, scaling to over 300 employees and treating hundreds of thousands of patients[1][4][6].
Oviva rides the growing trend of digital health and virtual care, particularly in managing chronic lifestyle-related diseases that impose significant burdens on healthcare systems globally. The timing is favorable due to increasing prevalence of obesity and diabetes, rising healthcare costs, and the shift toward remote care accelerated by the COVID-19 pandemic. By leveraging technology to deliver personalized, scalable interventions, Oviva helps reduce pressure on traditional healthcare providers and supports preventive care models. Its integration with national health systems exemplifies how digital therapeutics can be embedded into public healthcare, influencing broader adoption of tech-enabled chronic disease management across Europe[1][5][7].
Oviva is well-positioned to continue expanding its digital therapeutic offerings and geographic footprint in Europe, potentially entering new markets and broadening its range of chronic condition support. Trends such as increased digital health adoption, regulatory acceptance of digital therapeutics, and growing demand for cost-effective chronic disease management will shape its journey. Oviva’s influence may evolve from a digital dietetics leader to a comprehensive virtual clinic platform addressing multiple facets of lifestyle and chronic disease management, further integrating with healthcare systems and payers to improve population health outcomes at scale[1][7].
---
Note: There is a separate company named Oviva Therapeutics, founded in 2021 in New York, which focuses on developing first-in-class therapeutics for ovarian function and female healthspan extension. This biotech firm is distinct from the European digital health company Oviva and was acquired by Granata Bio in 2025[2][3]. The above overview pertains exclusively to the European digital health company Oviva.
Key people at Oviva.
Oviva has raised $113.0M in total across 3 funding rounds.
Oviva's investors include Marianne Bjørdal, Albion VC, Novartis Venture Fund.
Oviva has raised $113.0M across 3 funding rounds. Most recently, it raised $80.0M Series C in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $80.0M Series C | Marianne Bjørdal, Albion VC, Novartis Venture Fund | |
| Jan 1, 2020 | $21.0M Series B | Marianne Bjørdal, Albion VC, Novartis Venture Fund | |
| Nov 1, 2017 | $12.0M Series A | Marianne Bjørdal, Albion VC, Novartis Venture Fund |
